Growth Capabilities Resolian is expanding globally with a focus on bioanalytics for next generation biologics and cell and gene therapies, supported by acquisitions of PharmiWeb Ltd. and Denali Medpharma, and a leadership reshuffle that signals strategic growth. This creates selling opportunities to position Resolian as a single partner for end to end PK and ADME, bioanalytical assays, and QC across raw materials, formulated products, packaging and medical devices, enabling multi region trial support.

Global Footprint Denali Medpharma adds China based capabilities, complementing a US base in Malvern to offer compliant, locally supported analytics for Chinese and multinational sponsors. Target biotech and pharma clients with global development programs or China market considerations, presenting Resolian as a globally distributed CRO with integrated bioanalytics.

Comprehensive Services Breadth of services covers small and large molecules, including PK and metabolism expertise, plus testing across raw materials, finished products, packaging and devices for trace impurities, contamination and degradation. This end to end scope supports early to late stage programs and opportunities to upsell across the product lifecycle.

Mid-market Fit Financial scale and team size place Resolian in the mid market CRO tier, offering scalable resource models, flexible staffing, and faster turnarounds ideal for growing biotech and mid size pharma clients seeking reliable partners for expanding pipelines.

Leadership Partnerships Leadership changes, with the CEO transitioning to Chief Business Officer and President of Scientific Affairs, point to a focus on business development and strategic partnerships. Proactively engaging the new leadership with co development, exclusive collaboration, or multi project arrangements can accelerate deal flow.